Catabasis Pharmaceuticals (NASDAQ:CATB) says is has completed the enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy.
Top-line results from the Phase 3 PolarisDMD trial
are expected in Q4 of 2020 and the trial is anticipated to support an
NDA filing in 2021.
Source: Press Release
https://seekingalpha.com/news/3502706-catabasis-pharmaceuticals-moves-forward-polarisdmd-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.